Status: Recruiting
T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor
An open label, two-cohort, dose-escalation clinical study to evaluate the safety, anti-tumor activity and pharmacokinetics/pharmacodynamic (PK/PD) of NW-301V and NW-301D in subjects with advanced solid tumor.
Participants needed: 9
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Ting DengUpdated: Nov 25, 2025Locations: 1
Eligibility criteria
Age between 18-75 years [+4]
Received the following treatments: Cytotoxic chemotherapy within 2 weeks prior t... [+6]